2. Couser W.G., Remuzzi G., Mendis S., Tonelli M. The contribution of chronic kidney disease to the global burden of major non-communicable diseases. Kidney Int. 2011;80:1258–1270. Doi: 10.1038/ki.2011.368.

3. Gonzalez-Parra E., Tunon J., Egido J., Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovas. Pathol. 2012;21:372–381. Doi: 10.1016/j.carpath.2012.02.008.

4. Kasiske B.L., Zeier M.G., Chapman J.R., et al.; Kidney disease: improving global outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients:a summary. Kidney Int. 2010;77:299–311. Doi: 10.1038/ki.2009.377.

5. Giachelli C.M. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75:890–897. Doi: 10.1038/ki.2008.644.

6. Block G.A. Screening dialysis patients for vascular calcification. Semin Dial. 2010;23(3):271–276. doi: 10.1111/j.1525-139X.2010.00727.x.

7. Floege J., Kim J., Ireland E., et al.; ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol. Dial. Transplant. 2011;26:1948–1955. Doi: 10.1093/ndt/gfq219.

8. Tentori F., Blayney M.J., Albert J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2008;52(3):519–530. Doi: 10.1053/j.ajkd.2008.03.020.

9. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients:a national study. Am. J. Kidney Dis. 1998;31(4):607–617.

10. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN. 2004;15(8):2208–2218.

11. Slinin Y., Foley R.N., Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients:the USRDS waves 1, 3, and 4 study. JASN. 2005;16(6):1788–1793.

12. Lopes A.A., Tong L., Thumma J., et al. Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (dopps): evaluation of possible confounding by nutritional status. Am. J. Kidney Dis. 2012;60(1):90–101. Doi: 10.1053/j.ajkd.2011.12.025.

13. Kidney Disease: Improving Global Outcomes. (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD–MBD). Kidney Int. Suppl. 2009;113:S1–S130. Doi: 10.1038/ki.2009.188.

14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003;42:S1-S201.

15. Noori N., Kalantar-Zadeh K., Kovesdy C.P., et al. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2010;5(4):683–692. Doi: 10.2215/CJN.08601209.

16. Heng A.-E., Cano N.J.M. Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). NDT Plus. 2010;3:109–117.

17. Shinaberger C.S., Greenland S., Kopple J.D., et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am. J. Clin. Nutr. 2008;88:1511–1518. Doi: 10.3945/ajcn.2008.26665.

18. Lynch K.E., Lynch R., Curhan G.C., Brunelli S.M. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011;6:620–629. Doi: 10.2215/CJN.04620510.

19. Ritz E., Hahn K., Ketteler M., et al. Phosphate additives in food – a health risk. Dtsch. Arztebl. Int. 2012;109:49–55.

20. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin. Dial. 2007;20:295–301.

21. Penne E.L., van der Weerd N.C., van den Dorpel M.A., et al. Short-term effects of online hemodiafiltration on phosphate control:a result from the randomized controlled Convective Transport Study (CONTRAST). Am. J. Kidney Dis. 2010;55:77–87.

22. Kuhlmann M.K. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif. 2010;29:137–144. Doi: 10.1159/000245640.

23. Suri R.S., Garg A.X., Chertow G.M., et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71(4):349–359.

24. Movilli E., Camerini C., Gaggia P., et al. Effect of post-dilutional on-line haemodiafiltration on serum calcium, phosphate and parathyroid hormone concentrations in uraemic patients. Nephrol. Dial. Transpl. 2011;26(12):4032–4037. Doi: 10.1093/ndt/gfr179.

25. Martin K.J., González E.A. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin. J. Am. Soc. Nephrol. 2011;6(2):440–446. Doi: 10.2215/CJN.05130610.

26. Locatelli F., Altieri P., Andrulli S., et al. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial. Nephrol. Dial. Transplant. 2014;29(6):1239–1246. Doi: 10.1093/ndt/gfu031.

27. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780.

28. Covic A., Kothawala P., Bernal M., et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol. Dial. Transplant. 2009;24(5):1506–1523. Doi: 10.1093/ndt/gfn613.

29. Isakova T., Gutiérrez O.M., Chang Y., et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 2009;20:388–396. Doi: 10.1681/ASN.2008060609.

30. Cannata-Andia J.B. The use of phosphate binding agents is associated with lower mortality:results from the COSMOS study. 49th ERA-EDTA Congress, May 24–27, 2012. Paris, France.

31. Kakuta T., Tanaka R., Hyodo T., et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am. J. Kidney Dis. 2011;57(3):422–431. Doi: 10.1053/j.ajkd.2010.10.055.

32. Jamal S.A., Vandermeer B., Raggi P., et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease:an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277. Doi: 10.1016/S0140-6736(13)60897-1.

33. Chertow G.M., Burke S.K., Raggi P.; Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.

34. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824.

35. Block G.A., Raggi P., Bellasi A., et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441.

36. Spiegel D.M., Raggi P., Smits G., Block G.A. Factors associated with mortality in patients new to haemodialysis. Nephrol. Dial. Transplant. 2007;22:3568–3572.

37. Renagel®

38. Fosrenol®

39. Phoslyra®

40. Ренвелла®: инструкция по применению. URL: http://www.grls.rosminzdrav.ru

41. Akizawa T., Origasa H., Kameoka C., et al.; Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther. Apher. Dial. 2014;18:122–131. Doi: 10.1111/1744-9987.12068.

42. Вельфоро® 500: инструкция по применению. URL:http://www.grls.rosminzdrav.ru

43. Auryxia®

44. Daugirdas J.T., Finn W.F., Emmett M., Chertow G.M.; Frequent Hemo-dialysis Network Trial Group. The phosphate binder equivalent dose. Semin. Dial. 2011;24:41–49. Doi: 10.1111/j.1525-139X.2011.00849.x.

45. Daugirdas J.T., Chertow G.M., Larive B., et al.; Frequent Hemodialysis Network Trial Group. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J. Am. Soc. Nephrol. 2012;23:727–738. Doi: 10.1681/ASN.2011070688.

46. Daugirdas J.T., Blake P., Ing T. Bone disease. In: Handbook of dialysis. PA, 2015.

47. Savica V., Bellinghieri G., Monardo P., et al. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease:questions, myths and facts. J. Nephrol. 2013;26:456–464. Doi: 10.5301/jn.5000189.

48. Spiegel D.M., Block G.A. Should we be using calcium-containing phosphate binders in patients on dialysis? Nat. Clin. Pract. Nephrol. 2008;4:118–119.

49. Pflanz S., Henderson I.S., McElduff N., et al. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol. Dial. Transplant. 1994;9:1121–1124.

50. Saif I., Halim A., Altaf A., et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. J. Ayub. Med. Coll. Abbottabad. 2007;19:26–28.

51. Choy B.Y., Lo W.K., Cheng I.K.P. Effectiveness of calcium acetate as a phosphate binder in patients undergoing continuous ambulatory peritoneal dialysis. Hong Kong Med. J. 1998;4:23–26.

52. ОсваРен®: инструкция по применению. URL: http://www.grls.rosminzdrav.ru.

53. de Francisco A.L., Leidig M., Covic A.C., et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients:a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol. Dial. Transplant. 2010;25(11):3707–3717. Doi: 10.1093/ndt/gfq292.

54. Chertow G.M., Martin K.J. Current and future therapies for the medical management of secondary hyperparathyroidism. Semin. Dial. 1998;11:267–270.

55. Slatopolsky E., Burke S.K., Dillon M.A. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder lowers serum phosphorus and serum parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55:299–307.

56. Bleyer A.J., Burke S.K., Dillon M., et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999;33(4):694–701.

57. Hutchison A.J., Speake M., Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis:a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant. 2004;19:1902–1906.

58. Finn W.F., Joy M.S., Hladik G.; Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin. Nephrol. 2004;62:193–201.

59. Sprague S.M. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr. Med. Res. Opin. 2007;23:3167–3175.

60. Zhang C., Wen J., Li Z., Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226. Doi: 10.1186/1471-2369-14-226.

61. D’Haese P.C., Spasovski G.B., Sikole A., et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. 2003;63:S73.

62. Malluche H.H., Siami G.A., Swanepoel C., et al.; SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin. Nephrol. 2008;70:284–295.

63. Haratake J., Yasunaga C., Ootani A., et al. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am. J. Surg. Pathol. 2015;39:767–771. Doi: 10.1097/PAS.0000000000000385.

64. Wilhelm M., Gaillard S., Rakov V., Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin. Nephrol. 2014;81:251–258.

65. Phan O., Maillard M., Funk F., et al. Effect of Pa21, a new iron-based phosphate binder on fibroblast growth factor 23 (Fgf23) and vascular calcifications in uremic rats. J. Hypertens. 2015;33(1):e16–e17. Doi: 10.1097/01.hjh.0000467394.66592.05.

66. Wuthrich R.P., Chonchol M., Covic A., et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2013;8:280–289. Doi: 10.2215/CJN.08230811.

67. Floege J., Covic A.C., Ketteler M., et al.; PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–647. Doi: 10.1038/ki.2014.58.

68. Floege J., Covic A.C., Ketteler M., et al.; Sucroferric Oxyhydroxide Study Group. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol. Dial. Transplant. 2015;30:1037–1046. Doi: 10.1093/ndt/gfv006.

69. Parameswaran V., Ficociello L.H., Van Zandt C.R., et al. Pill Burden and Serum Phosphorus in Hemodialysis Patients Switched from Sevelamer to Sucroferric Oxyhydroxide . J.Am. Soc.Nephrol. 2016;27:FR–PO 428.

70. Sprague S.M., Covic A.C.,·Floege J., et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin d receptor agonist bioactivity in dialysis patients. Am. J. Nephrol. 2016;44:104–112. Doi: 10.1159/000447600.

71. Yaguchi A., Yonekubo S., Maruyama I., et al. Comparison of Phosphate Binding Capacities of PA21, a novel phosphate binder, with those of other phosphate binders in vitro and in vivo. Drug Res. 2016;66(5):262–269. Doi: 10.1055/s-0035-1569328.

72. Dwyer J.P., Sika M., Schulman G., et al.; Collaborative Study Group. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients:a short-term randomized trial. Am. J. Kidney Dis. 2013;61:759–766. Doi: 10.1053/j.ajkd.2012.11.041.

73. Van Buren P.N., Lewis J.B., Dwyer J.P., et al.; Collaborative Study Group. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am. J. Kidney Dis. 2015;66 :479–488. Doi: 10.1053/j.ajkd.2015.03.013.

74. Lewis J., Sika M., Koury M., et al.; Collaborative Study Group. Ferric citrate controls phosphorus and delivers iron in dialysis patients. J. Am. Soc. Nephrol. 2015;26:493–503. Doi: 10.1681/ASN.2014020212.

75. Cheng S.C., Young D.O., Huang Y., Delmez J.A., Coyne D.W. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phos-phorus in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008;3:1131–1138. Doi: 10.2215/CJN.04211007.

76. Block G.A., Persky M.S., Shamblin B.M., et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney dis-ease. Nephron. Clin. Pract. 2013;123:93–101. Doi: 10.1159/000351850.